通道化噎丸联合放疗治疗Ⅲ期食管癌的临床观察  

Clinical Observation on Tongdao Huaye Pill Combined with Radiotherapy in the Treatment of StageⅢEsophageal Cancer

作　　者：田青 杨亚 周超锋[1] 周世繁[1] 张瑜 王赛[1] 郭志忠[1] TIAN Qing;YANG Ya;ZHOU Chao-feng;ZHOU Shi-fan;ZHANG Yu;WANG Sai;GUO Zhi-zhong(Department of Oncology,Henan Provincial Hospital of Traditional Chinese Medicine,Zhengzhou 450000 Henan,China;Department of Radiotherapy,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000 Henan,China)

机构地区：[1]河南省中医院肿瘤科,河南郑州450000 [2]郑州大学第一附属医院放疗科,河南郑州450000

出　　处：《中医肿瘤学杂志》2024年第3期32-36,共5页Journal of Oncology in Chinese Medicine

基　　金：第二批国家中医临床研究基地科研专项(编号:2019JDZX006);河南省中医药科学研究专项课题(编号:2022ZYZD11)。

摘　　要：目的观察通道化噎丸联合放疗治疗Ⅲ期食管癌的1年复发率和临床疗效。方法选取2022年1月至2023年12月在河南省中医院及郑州大学第一附属医院接受根治性放疗后的60例食管癌患者,采用随机数字表法分为两组,其中观察组30例为根治性放疗后3周~6周内接受通道化噎丸口服治疗,对照组30例为根治性放疗后定期临床观察,评价其1年复发率、中医证候积分、生活质量评分及不良反应发生情况。结果观察组1年复发率为50%,对照组1年复发率为77%。治疗3个月后,观察组治疗后中医证候积分改善优于对照组,差异具有统计学意义(P<0.05),治疗结束后,通过两组生活质量评分比较,观察组有效率高于对照组,差异有统计学意义(P<0.05),观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论通道化噎丸联合放疗治疗Ⅲ期食管癌,可降低1年复发率,提高患者生活质量。Objective To observe the one-year recurrence rate and the clinical efficacy of Tongdao Huaye Pill combined with radiotherapy in treating stageⅢesophageal cancer.Methods 60 cases with esophageal cancer who had been treated with radical radiotherapy in Henan Provincial Hospital of Traditional Chinese Medicine(TCM)and the First Affiliated Hospital of Zhengzhou University from January 2022 to December 2023 were divided into two groups by random number table method.The observation group of 30 cases were treated with Tongdao Huaye Pill within 3~6 weeks after radical radiotherapy,while the control group of 30 cases underwent clinical observation periodically after radical radiotherapy.The one-year recurrence rates,TCM clinical symptom scores,quality of life scores,and incidences of adverse reaction were evaluated.Results The one-year recurrence rate was 50%in the observation group and 77%in the control group.Three months after treatment,the TCM syndrome score of the observation group was superior to that of the control group,which was statistically significant(P<0.05).After treatment,the effective rate of the observation group was higher than that of the control group by comparing KPS scores,and the difference was statistically significant(P<0.05).Meanwhile,the incidence of adverse reactions in the observation group was lower than that of the control group,which was statistically significant(P<0.05).Conclusion The treatment of Tongdao Huaye Pill combined with radiotherapy for stageⅢesophageal cancer can reduce the one-year recurrence rate,and improve the quality of life for the patients.

关 键 词：食管癌 放疗 复发率 通道化噎丸 

分 类 号：R730.52[医药卫生—肿瘤] R273[医药卫生—临床医学] R735.1